Anavex Life Sciences Corp (AVXL)

[Talon38]

Mapman and many others have supplied a number of peer reviewed abstracts on Sigma-1 research while the the pre-clinical/clinical research on 2-73 for Alzheimer's, Parkinson's, Fragile X, Angelman's and Epilepsy has been conducted by very credible academic, medical and governmental entities like the University of Montpellier, Dresden University, The German Health Authority, Rosekamp Institute, Australian Health Authority, FDA, Melbourne/Alfred Health, University of South Florida, National Academy of Science, NIH, MJFF, FRAXA Research Foundation, Foundation for Angelman Syndrome, Baylor College of Medicine, Rett Syndrome Foundation, Lund University, MaGill University, and Wayne State University.

Three National Health Authorities, three Health Agencies, seven Universities, and four foundations along with presentations at a number of prestigious medical conferences says a lot about the vetting of the Sigma-1 concept and our drug.........that Anavex is carefully and thoroughly developing 2-73's wide application in a significant number of neurodegenerative diseases is very hard to dispute.

-------------

From Mapman's and my earlier posts

i found this interesting paper on PubMed that the more scientifically inclined may find worthwhile.

Quote:
This review will focus on the role of MAMs in amyotrophic lateral sclerosis (ALS) and hereditary motor and sensory neuropathy, two neurodegenerative diseases particularly affecting neurons with long projecting axons. We will discuss how defects in MAM signaling may impair neuronal calcium homeostasis, mitochondrial dynamics, ER function, and autophagy, leading eventually to axonal degeneration. The possible impact of MAM dysfunction in glial cells, which may affect the capacity to support neurons and/or axons, will also be described. Finally, the possible role of MAMs as an interesting target for development of therapeutic interventions aiming at delaying or preventing neurodegeneration will be highlighted.


Quote:
Furthermore, MAM dysregulation occurs in several neurological pathologies including Alzheimer’s disease, Parkinson’s disease, and motoneuron diseases10–12.


Quote:
SIGMAR1 (sigma-1 receptor) recessive mutations were identified in both adult-onset137 and juvenile-onset ALS (ALS16)33,36 and also in patients affected with distal HMN (dHMN)34,35. SIGMAR1 is an ER chaperone protein present in MAMs and strongly expressed in motoneurons38,160. The mutated SIGMAR1 protein is unstable and non-functional, probably acting in a loss-of-function manner36.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832431/

--------

other abstracts

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603014/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832754/